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Advances in perinatal care have dramatically improved survival of extremely preterm infants
and the incidence of bronchopulmonary dysplasia (BPD) has not changed over the past few
decades, which likely reflects the impact of increased survival of extremely preterminfants.1
BPD remains the most common late morbidity of preterm birth, but many controversies
persist regarding how to best define BPD, grade its severity, and prevent disease.2 Ongoing
clinical care and research have largely focused on issues regarding the pathogenesis and
prevention of BPD in preterm infants with the important goal of reducing the incidence of
BPD at 36 weeks corrected age, with a focus on respiratory care related issues during the
early neonatal intensive care unit (NICU) course.3 However, some preterm infants develop
particularly severe chronic respiratory disease and have related comorbidities that persist
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throughout their NICU course and post-discharge, as reflected by the prolonged need for
high levels of respiratory support, including mechanical ventilation and high inspired
oxygen concentrations. The management of infants with severe BPD (sBPD) has received
less attention regarding clinical studies and interventions when compared with preventive
strategies, yet these infants constitute a critical population who remain at high risk for
extensive morbidities and late mortality (Figure 1).

Author Manuscript
Author Manuscript

Based on consensus recommendations from a National Institutes of Health (NIH) workshop,
BPD is commonly defined by the requirement for supplemental oxygen at 28 days in infants
born at below 32 weeks gestation.4 Furthermore, BPD is divided into 3 severity grades
(mild, moderate, or severe) based on respiratory support needs at 36 weeks postmenstrual
age (PMA) (Table I). The incidence of sBPD is inversely correlated with gestational age and
remains 16% for all infants born at <32 weeks (Table I).5 Unfortunately, high-quality
evidence on which to base the care for infants and children with sBPD and consensus care
guidelines are lacking. These knowledge gaps have contributed to marked variability in care
within and between NICUs throughout the country. Current NIH definitions of BPD are
almost exclusively focused on NICU-related issues, with limited discussion regarding longterm respiratory outcomes throughout infancy, childhood, and adulthood. In addition, the
classification of sBPD is very broad and fails to differentiate between proposed phenotypes
of infants with a persistent oxygen requirement and/or need for continuous positive airway
pressure (CPAP) or high flow nasal cannula at 36 weeks postconceptual age who have
relatively less severe respiratory disease (type 1 sBPD; Table I) from those with more
extreme BPD (or type 2 sBPD), who remain ventilator-dependent and more often have
severe complications, including pulmonary hypertension, poor growth, and
neurodevelopmental problems. Understanding distinct antenatal, early postnatal, genetic, or
epigenetic factors, or comorbidities that contribute to sBPD, especially the more severe
phenotype (type 2 sBPD), are critical for enhancing late outcomes in this subgroup.

Author Manuscript

Clinical needs of infants with type 2 sBPD who require ongoing respiratory support beyond
term corrected age are diverse and complex, and management strategies that optimize
survival and long-term outcomes are controversial and uncertain. Several factors contribute
to increased morbidity and mortality in this population. First, there are few evidence-based
strategies to improve outcomes. Second, patients with chronic ventilator-dependent BPD
have historically been cared for in acute care settings. Management strategies for chronic
disease differ considerably from acute respiratory failure, especially regarding approaches to
mechanical ventilation. When compared with approaches toward acute respiratory failure,
neonatal and pediatric intensivists may have less experience with ventilator management of
infants with severe chronic lung disease. Most importantly, poor communication between
providers, subspecialists, nursing staff, and families during prolonged hospitalization may
lead to inconsistent care and adverse outcomes. High staff turnover and infrequent
communication among the doctors and bedside staff as well as between parents and the
medical team may contribute to these inconsistencies. These infants have complex clinical
courses with multiple morbidities, including frequent hospitalizations throughout childhood,
and often with poor continuity of care. Interdisciplinary care teams have the potential to
alleviate many of these issues and improve outcomes for these infants.
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Based on these concerns, a group of clinicians from interdisciplinary care programs for
infants with sBPD at several major medical centers, including neonatologists,
pulmonologists, critical care physicians, gastroenterologists, nurse specialists, and others,
formed the “BPD Collaborative,” to address controversies and promote research to enhance
the care of children with sBPD. In this review, we present an interdisciplinary approach to
patients with sBPD and their families throughout the NICU and outpatient courses.
Emphasis is placed on the rationale for developing the team approach to chronic care as well
as highlighting key gaps in knowledge in our care for infants with sBPD, which would likely
improve with multicenter investigations.

Incidence and Etiology of sBPD

Author Manuscript
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Although marked improvements in care have led to milder respiratory courses for most
preterm infants, sBPD remains a major problem. In the validation study from the Eunice
Kennedy Shriver National Institute of Child Health and Human Development Neonatal
Research Network, the incidence of sBPD was 16% in infants born at <32 weeks and
weighing <1000 g (Table I).5 Reports using birth cohorts from Scandinavia found that the
incidence of sBPD was 25% in infants born at <27 weeks gestation in Sweden, and 20% in
infants born at <28 weeks in Norway.6,7 The Children’s Hospital Neonatal Consortium
reported a 16% incidence of sBPD of patients born at <32 weeks, of whom 91% survived to
discharge, 66% were discharged on supplemental oxygen, 4% on mechanical ventilation,
and 5% received tracheostomy.8 The BPD Collaborative reported a point prevalence of
sBPD of 36.5% with a range across centers of 11%–58%, and 41% of the patients with
sBPD had type 2 sBPD with a range of 0%–68%.9 Using an estimated incidence of sBPD of
16% for infants born at <32 weeks suggests that ~13 000 patients develop sBPD annually in
the US alone.5
Epidemiologic data are limited, but estimates suggest that roughly 8000 children in the US
receive mechanical ventilation at home.10 Based on 2011 data from the state of
Pennsylvania’s Ventilator Assisted Children’s Home Program, 36% of ventilator-dependent
children were diagnosed with chronic lung disease, 77% of these specifically with the
diagnosis of sBPD.10 From these data, it can be extrapolated that ~2000 infants and children
with sBPD are dependent on mechanical ventilation at home in the US.

Author Manuscript

The exact pathogenic mechanisms underlying the development of sBPD in preterm infants
and factors that favor the development of sBPD are uncertain. Similarly, factors that
contribute to the receipt of prolonged mechanical ventilation within the subgroup with type
2 sBPD are uncertain. The incidence of sBPD is inversely related to gestational age at
birth.6,11,12 Male infants are more likely to develop sBPD and the need for mechanical
ventilation. Patent ductus arteriosus, sepsis, and surgical necrotizing enterocolitis are
strongly associated with the development of sBPD.11 A recent preclinical study suggests
dose-related effects of antenatal endotoxin as a model for experimental chorioamnionitis that
is sufficient to induce sBPD, and moderate oxygen treatment actually improved lung
structure rather than worsening respiratory outcome, suggesting the complexity of pre- and
postnatal events in driving BPD phenotypes.13
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The genetics and epigenetic, or gene/environmental factors, underlying the risk for sBPD
remain to be determined, however, recent twin studies have demonstrated a genetic
component to the development of BPD in general,14,15 and there are an increasing number
of gene-targeted studies finding specific mutations in genes associated with lung
development, immunity, and oxidative stress associated with BPD in preterminfants.16–21
However, specific genes that increase the risk for sBPD remain unknown. In particular, data
are lacking that specifically address whether distinct genetic, epigenetic, or other etiologic
mechanisms contribute to the development of sBPD in comparison with milder forms of
BPD. In addition, there is a clear need to develop biomarkers and other predictors for the
early identification of preterm newborns who are at risk for BPD and more specifically for
sBPD.

Clinical Features of sBPD
Author Manuscript
Author Manuscript

Although perhaps less common than in the past, infants with sBPD present persistent
challenges, raise many questions regarding optimal strategies for enhancing outcomes, and
may at times present significant ethical dilemmas. Furthermore, there is limited high quality
evidence on which to base clinical management of the patient with sBPD. Evaluation of the
patient with sBPD can include a variety of studies discussed herein, which should be guided
by clinical presentation. In the extreme preterm infant with type 2 sBPD with the usual
NICU course, there is little need to exclude other potential causes of chronic lung disease. In
the infant with an atypical presentation or NICU course, potential causes of chronic neonatal
respiratory failure include surfactant protein deficiency, gastroesophageal reflux disease
(GERD), cystic fibrosis, immune deficiency, anatomic heart disease, pulmonary infection,
H-type tracheoesophageal fistula, primary ciliary dyskinesia, and other developmental lung
diseases. Evaluations may include bronchoscopy, echocardiogram, esophageal pH and
impedance probes, genetic testing, chest computed tomography scan, lung biopsy, and other
studies.

Author Manuscript

The NIH consensus statement that defined BPD severity4 did not address the wide range of
disease severity within the group classified as sBPD. In 2003, the American Thoracic
Society published a consensus statement pertaining to the care of children with BPD
emphasizing the need for an interdisciplinary approach to address the multiorgan sequelae of
premature birth.22 More specifically, infants with type 2 sBPD are at increased risk for
adverse comorbidities including neurodevelopmental impairment, pulmonary hypertension
(PH), GERD, feeding difficulties, airways disease, retinopathy of prematurity, and systemic
hypertension. These comorbidities frequently complicate the course in sBPD, require the
involvement of multiple subspecialists, and, when not integrated into the overall
management plan, can further exacerbate gaps in communication and care. In centers that
have adopted an interdisciplinary approach to care, survival for this subset of infants is over
75%–80% at discharge.9,23 Because of the low incidence of type 2 sBPD at any single
center, this population remains understudied, and many gaps in knowledge (Table II24) and
controversies exist regarding optimal clinical strategies to improve outcomes in this
subgroup of infants.
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Mechanical Ventilation in sBPD
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The strategy for respiratory support in the acute phases of extreme prematurity is to avoid
unnecessary intubation and mechanical ventilation to prevent secondary ventilatorassociated lung injury. Persistent need for mechanical ventilator support at postnatal day 7 is
associated with high risk for BPD,11 however, the link between BPD risk and sustained
ventilator support at this time point may simply reflect the critical impacts of adverse
antenatal and early postnatal events on lung structure and not merely be due to ventilatorassociated lung injury alone. Recent multicenter trials no longer support intubation solely for
the purpose of treatment with exogenous surfactant.25–27 Unfortunately, a significant
proportion of infants cannot be stabilized and supported on nasal CPAP during their entire
hospital course. Several recent trials have shown that infants randomized to immediate nasal
CPAP were intubated secondary to apnea or respiratory failure in at least 50% of cases.25–27
Hence, the proportion of infants exposed to intubation and mechanical ventilation remains
high along with a continued high incidence of chronic respiratory failure and the subsequent
development of sBPD. In extremely low birth weight infants in the first week of life,
attempts at extubation to and stabilization on nasal CPAP are still warranted, based on the
potential impact of prolonged ventilator support on sBPD and adverse neurodevelopmental
outcomes.28

Author Manuscript

However, at some point during the respiratory course of premature infants with evolving
BPD, lung structure and function may become sufficiently abnormal that attempts at
extubation to nasal CPAP are neither feasible nor desirable. Some indicators include
sustained respiratory distress with retractions, recurrent cyanotic or bradycardic episodes,
intolerance of respiratory and physical therapies or handling, poor growth, and the apparent
use of or need for repeated steroid courses without sustained benefit. At this point, the goals
of care need to be redirected toward optimizing management on mechanical ventilation to
support adequate gas exchange, reduce the work of breathing, and optimize growth and
healing of the injured lungs. Resolution of the lung disease and improvement in lung
function depends on emphasizing nutritional strategies that enhance somatic and lung
growth.
Matching Ventilator Strategies with Lung Mechanics in sBPD

Author Manuscript

Determining the specific type and level of respiratory support for infants with sBPD is
challenging, as an optimal ventilator strategy required by these infants is frequently
dramatically different than the strategy utilized in the first few weeks of life (Table III).29
The strategy must reflect the transition from lung mechanics in the first few days of life,
which are dominated by low compliance, relative homogeneity, and normal airway
resistance, to the mechanics that are seen in sBPD, dominated by high airway resistance, air
trapping, and heterogeneous aeration (Figure 2).29 In the first week of life, lung mechanics
suggest that a ventilator strategy aimed at the relatively uniform respiratory system with
short time constants is reasonable and would include a fast rate, low tidal volume (Vt), short
inspiratory time (Ti) strategy (Figure 2).29–31 In sBPD, the lung is characterized by different
combinations of lung regions with different levels of airway resistance and altered distal
lung compliance, which leads to highly diverse time constants (Figure 2). Thus, to enhance
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gas exchange, reduce the risk for atelectasis, decrease dead space ventilation, and perhaps
lower pulmonary vascular resistance, the ventilator support strategy needs to change
dramatically from a fast-rate, low Vt strategy during the early course to a slow-rate, high Vt
and prolonged Ti strategy for chronic disease (Table III).

Author Manuscript

As lung mechanics change over time in infants with sBPD who are on relatively low
concentrations of supplemental oxygen and moderate or high rates, it is not uncommon to
observe acute episodes (“spells”) of respiratory distress associated with high to fraction of
inspired oxygen (FiO2) requirements, which are often difficult to address by simple
maneuvers on the ventilator. At this stage, hypercarbia is often present with radiographic
findings of hyperinflation alternating with areas of haziness and atelectasis. The timing of
onset of these episodes in ventilated infants is variable, although these often develop during
the first month of life. Some episodes of acute deteriorations in oxygenation may represent
loss of volume during forced exhalation, leading to intrapulmonary shunt.32 These events are
usually brief and self-limited, but may be frequent. These “breath-holding spells” are likely
a separate phenomenon from the more prolonged events that may be associated with striking
elevations of partial pressure of carbon dioxide (PaCO2), suggesting marked airways
obstruction because of mucus plugging, aspiration, or central airway dynamic collapse.
Approaches to severe spells include vigorous suctioning, airway cultures to diagnose
ventilator-associated pneumonia, transitioning mechanical ventilator strategies to provide
better support to maintain lung volume, and consideration of a trial of drug therapy, such as
a steroid “burst,” bronchodilators, and/or diuretics. Although many infants get treated with
bronchodilators and diuretics, their use between centers is highly variable.33,34

Author Manuscript

A single center study of preterm infants reported that infants on mechanical ventilation at 30
days with a respiratory severity score of >6 (defined as mean airway pressure × FiO2) were
more likely to succumb to respiratory failure and were ventilated longer than infants with a
respiratory severity score <6 at that time point.35 These data suggest that abnormal lung
function develops well before 1 month of life and that with progressive respiratory
instability, one should consider changing the respiratory support strategy to alter ventilator
strategy to include a slow rate, larger Vt, and increased Ti to maintain minute ventilation and
functional residual capacity.

Author Manuscript

Whether the use of volume targeted or pressure-limited ventilation is best with sBPD is
uncertain, however, chronic respiratory support strategies require higher tidal volumes than
those used with early “lung protective” strategies during the acute phases of disease.29,31
The targeted Vt for acute short time constant disease is typically in the range of 4–6 mL/kg,
whereas for infants with developing obstructive airway disease the Vt may be 8–12 mL/kg.
For pressure ventilation, the peak inflation pressure needed to generate this Vt can be well
above 25 cm H2O, depending on the individual patient’s underlying airways resistance, lung
compliance, and related respiratory system mechanics. These higher pressure settings reflect
the need to provide sufficient Vt in lung disease that is generally characterized by high total
respiratory system resistance and lower compliance. Furthermore, Ti are usually increased
(0.5–0.8 seconds) to allow for better gas distribution into distal lung units, but longer Ti and
increased Vt requires the use of a slow ventilator rate (often below 20 breaths per minute) to
allow for sufficient emptying to avoid hyperinflation. Faster rates with increased Vt and
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prolonged Ti may worsen gas trapping and patient-ventilator asynchrony. Monitoring flow
waveforms can aid in determining whether expiratory flow has been completed before the
next breath is delivered.

Author Manuscript

Although generally counterintuitive in the setting of hyperinflation, positive end expiratory
pressure (PEEP) should be relatively high (>6–8 cm H2O) to optimize gas exchange,
maintain functional residual capacity, avoid regional atelectasis, and avoid the adverse
effects of “inadvertent PEEP.” In some patients with significant airways closure especially
with tracheomalacia or bronchomalacia, PEEP may need to be even higher to keep airways
open during active exhalation. Flow-volume loops of patients with sBPD often show
expiratory flow limitation at low lung volumes when lower PEEP levels are used, which is
due to expiratory collapse of poorly supported small airways and air-trapping. With this
pattern, PEEP can usually be titrated upward until this expiratory flow limitation is resolved
by visual inspection of flow-volume loops. Questions regarding the use of this ventilator
strategy for established sBPD include concerns for further inducing volutrauma because of
additional lung overdistension, but when combined with lower ventilator rates and sufficient
expiratory time, additional gas trapping is rare with this approach. Presently, there are no
clinical trials to validate the strategy of low rate and large tidal volume ventilation, but this
strategy is well-grounded with clinical experience and follows our current understanding of
the pathophysiology of sBPD.29,31,36 For the very small number of patients with severe BPD
who do not respond to this mechanical ventilation strategy, the practitioner must then
consider rare but important causes of hypoxemia and ventilation-perfusion mismatch.

Author Manuscript

Structure-function studies in the nonresponsive patient with sBPD may identify other
abnormalities such as predominantly restrictive lung disease, tracheobronchomalacia, and/or
other rare causes of ventilation-perfusion mismatch.

Author Manuscript

In acute care, rapid weaning from mechanical ventilation is encouraged to avoid the
potential adverse effects of prolonged intubation and ventilator support. In contrast, the goal
of mechanical ventilation in the chronic phase of the ventilated infant with sBPD is to
provide relatively stable respiratory support to reduce respiratory distress, improve gas
exchange as reflected by lower FiO2, minimize intermittent “spells,” enhance tolerance of
care and handling, and reduce the need for chronic sedation. Additional goals include
preventing the development or progression of PH, providing optimal nutrition for quality
growth, and encouraging developmental outcomes. These clinical variables of respiratory
stability better reflect successful strategies than traditional metrics of PaCO2 or end-tidal
carbon dioxide (CO2), which are unreliable in this setting. There is a slow but steady
decrease in the amount of oxygen needed to provide stable saturations and sometimes even
the Vt can be weaned. The focus should be on lowering the oxygen concentration in this
phase of the healing disease and once infants are stable in less than 40% oxygen to achieve
oxygen saturation (SpO2) values ≥ 92%, extubating to noninvasive respiratory support is
considered and is usually successful even from relatively high Vt.
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Considerations for Tracheostomy Placement and Commitment to Chronic Ventilator
Support

Author Manuscript

The decision to commit an infant with sBPD to chronic ventilator support with the
placement of a tracheostomy tube can be complex and difficult and must involve extensive
discussions among care providers and family members. Many factors contribute to this
decision, but the overall goal of chronic mechanical ventilator support is to reduce the
severity of respiratory distress, including retractions, head-bobbing, dyspnea, and “spells,”
to provide clinical stability that will enhance survival and optimize long-term
developmental, neurocognitive, and growth-related outcomes. Tracheostomy placement is
only part of an organized strategy to provide chronic ventilation and allows focus to shift
toward enhancement of long-term outcomes. In some settings, tracheostomy represents a
symbol of “futility” that may lead to some reluctance to perform tracheostomy and commit
to ventilator support. Tracheostomy placement should not be viewed as a method for rapidly
weaning of respiratory support but rather a means for sustained mechanical ventilation,
relieving distress and providing the respiratory stability that is necessary to enhance
neurocognitive, behavioral, and developmental outcomes. Nonetheless, determination of the
efficacy and optimal timing of tracheostomy for infants with type 2 sBPD remains to be
determined.

Author Manuscript

Beyond tracheostomy placement, an interdisciplinary team of collaborating subspecialists
and therapists can provide continuity of care for these children. Teams of experienced
personnel may coordinate care plans through regular rounds, family meetings, and
collaboration with the attending service that will alleviate problems attributable to rapid
turnover of staff in the intensive care unit setting. Thus, emphasis should be directed toward
the role of sustained mechanical ventilation to promote growth and development, as
supported by an interdisciplinary care team, and not on simply the placement of a
tracheostomy.

Pulmonary Hypertension in sBPD

Author Manuscript

Our approach to PH in sBPD is to have a high index of suspicion and, when PH is found, to
rigorously evaluate patients for underlying respiratory morbidities and to treat the lung
disease aggressively (Table IV). PH complicates the course in up to 25% of patients with
sBPD,38 therefore, screening echocardiograms should be performed in all patients with
sBPD. Some cases of PH might be missed with the use of echocardiography alone;39
nevertheless, it remains the best non-invasive screening tool to assess PH in sBPD. Even
though the accuracy of the echocardiogram may be limited regarding the ability to find a
measurable and reproducible tricuspid regurgitant jet velocity to estimate right ventricular
systolic pressure, other markers of PH, such as septal wall flattening and right ventricular
dilation, may be clinically useful.24
If the screening echocardiogram is initially normal, subsequent echocardiograms should be
performed in patients with sBPD at 1- to 2-month intervals until the respiratory status of the
patient is significantly improved. If, on the other hand, the screening echocardiogram
demonstrates PH, the initial clinical strategy for the management of PH in infants with BPD
begins with optimizing the treatment of the underlying lung disease (Table IV).37 Periods of
J Pediatr. Author manuscript; available in PMC 2017 August 18.
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acute hypoxemia, whether intermittent or prolonged, contribute to the pathogenesis of late
PH in sBPD and also exacerbate existing PH. Therefore, oxygen saturation limits may need
to be changed to avoid intermittent or sustained hypoxemia with targets generally between
92% and 95%.37 Indeed, in patients with BPD and severe PH who also have significant
respiratory distress and high levels of respiratory support, the presence of PH may provide a
stronger rationale for long-termmechanical ventilatory support with tracheostomy. Changes
in serial blood brain natriuretic peptide and N-terminal pro-brain natriuretic peptide levels
may provide additional guides to aid the management of PH in sBPD.

Author Manuscript

Cardiac catheterization can be used to guide therapy, particularly in severe cases and in cases
requiring long-term therapy.37 Although cardiac catheterization prior to the initiation of
long-term therapy is encouraged, the risks and benefits of this procedure in sick newborns
depend on local expertise with the procedure and severity of disease. The goals of cardiac
catheterization are to assess the severity of PH; exclude or document the severity of
associated anatomic cardiac lesions; define the presence of systemic-pulmonary collateral
vessels, pulmonary venous obstruction, or left heart dysfunction; and to assess pulmonary
vascular reactivity in patients who fail to respond to oxygen therapy alone.37 In particular,
several key factors that may affect cardiopulmonary function include assessment of shunt
lesions, especially atrial septal defects; the presence, size, and significance of bronchial or
systemic collateral arteries; the presence of pulmonary vein stenosis; and structural
assessments of the pulmonary arterial and venous circulation by angiography.

Author Manuscript

Despite the growing use of pulmonary vasodilator therapy for the treatment of PH in BPD,
data demonstrating efficacy are extremely limited, and these agents should be used only after
thorough diagnostic evaluations and aggressive management of the underlying lung disease
(Table V).24,37 Current therapies used for PH therapy in infants with BPD generally include
inhaled nitric oxide (iNO), phosphodiesterase type 5 inhibitors, endothelin receptor
antagonists, and calcium channel blockers (CCBs). In a small number of patients with sBPD
undergoing cardiac catheterization, iNO decreased pulmonary artery pressure and the ratio
of pulmonary vascular resistance to systemic vascular resistance, which was further
augmented with supplemental oxygen.40 Calcium channel blockers (such as nifedipine)
benefit some patients with PH, and short-term effects of these agents in infants with BPD
have been reported.41,42 However, CCBs can cause systemic hypotension and suppress
myocardial function, especially in young infants with left ventricular dysfunction. In
comparison with acute iNO reactivity in a small number of infants studied with sBPD, the
acute response to CCBs was minimal.40

Author Manuscript

Sildenafil or bosentan (an endothelin receptor antagonist) are frequently used for long-term
therapy of PH in infants with BPD.43 Sildenafil, a highly selective type 5 phosphodiesterase
inhibitor, augments cyclic guanosine monophosphate content in vascular smooth muscle and
has been shown to benefit adults with PH as monotherapy and in combination with standard
treatment regimens.44,45 In a study of infants with chronic lung disease and PH, prolonged
sildenafil therapy was associated with improvement in PH by echocardiogram in most
patients (88%) without significant adverse events.46 Although the time to improvement was
variable, many patients were weaned from mechanical ventilator support and other PH
therapies during the course of sildenafil treatment without worsening of PH.46 The
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recommended starting dose for sildenafil is 0.5 mg/kg/dose every 8 hours. If there is no
evidence of systemic hypotension, this dose can be gradually increased over 2 weeks to
achieve desired pulmonary hemodynamic effect or a maximum of 2 mg/kg/dose every 6–8
hours. Data on other agents, such as endothelin receptor antagonists and prostacyclin
analogs, are limited in infants with BPD who fail to respond to other approaches.37 Recent
studies suggest that chronic treprostinil infusion by subcutaneous delivery may provide
additional benefit in infants with BPD and PH that is poorly responsive to other
medications.47,48

Nutritional Management in sBPD

Author Manuscript

Infants with sBPD provide unique nutritional challenges partly because of periods of
hypermetabolic states, increased work of breathing, growth suppression from chronic stress
and inflammation, and chronic steroid or diuretic use. The goal of nutrition in BPD is to
deliver adequate constituents that match the patient’s specific needs, but these needs change
with time in infants with sBPD. Optimal nutrition requires an understanding of multiple
factors that can affect somatic growth and also slow organ growth over time. Long-term
pulmonary outcome studies highlight the persistence of abnormalities in lung development
even into young adulthood, demonstrating the complexity of determining the nutritional
state in these infants and defining their nutritional support requirements.
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Unfortunately, data regarding optimal nutritional interventions in patients with sBPD are
limited. It is known that infants with sBPD grow more poorly than preterm infants without
BPD, and neonates with the slowest growth velocities are associated with a high risk for
sBPD. Adequate nutrition, including micronutrient and vitamins A, D, and C
supplementation, is likely critical for lung growth, development, function, and repair. The
role of growth factors and their suppression by stress and inflammation have been shown to
underlie the nutritional imbalance in sBPD, and monitoring of somatic growth by weight and
length is essential. Despite improvements in nutritional intake and growth over the past
decade, infants with sBPD often continue to demonstrate growth failure. Many studies only
report weight gain, although there is strong recognition of the importance of linear growth.
Better nutritional measures have also been shown to correlate with better
neurodevelopmental outcomes in infants with BPD.49
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Nutritional assessments should include a review of prenatal and past medical history, birth
weight z scores, anthropometric data, medication exposure, biochemical data, and clinical
status. Anthropometric data including measurements of weight, length, and head
circumference are the most common methods used for monitoring postnatal growth and are
compared with reference data. Individual patient data should be plotted and followed with an
infant growth chart to better assess changes in growth trajectories. Although weight can be
measured easily and accurately, it is influenced by fluid status and may not always reflect
changes in lean body mass. Linear growth is widely regarded as the best measure of
assessing adequacy of dietary intake and is associated with lean body mass accretion and
organ growth and development. Measuring length in a precise and reproducible manner
often poses a challenge. Use of a recumbent length board to measure crown-heel length
should be a standard of practice in assessing linear growth in this patient population. Weight
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for length status should be assessed for proportionality to avoid developing overweight.
Persistent weight gain at a rate that crosses growth chart percentiles without the same pattern
demonstrated in linear growth warrants a re-evaluation in energy intake and is often
associated with a change in the clinical status of the patient. Intrauterine growth retardation
and/or small for gestational age are high-risk conditions for developing sBPD and may set
the stage for persistent abnormal growth patterns in the postnatal period. Small for
gestational age status has also been associated with an increased risk for PH in sBPD.50
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Caloric demands are likely high to meet the metabolic requirements for growth and healing.
This may be achieved with the use of highly fortified mother’s breast milk or calorically
dense formula feedings. Consistent with American Academy of Pediatrics
recommendations, mother’s breast milk should be used through the first 6 months of life.
Energy intakes >130 kcal/kg/day may be required in these infants, particularly during the
more unstable phase of BPD, whereas older infants in the more stable respiratory phase of
BPD may require much less depending upon the level of activity and stability. Although
excessive calories may increase CO2 production, past studies implicate a dietary imbalance
of high carbohydrate to low fat that is particularly problematic in children and adults with
chronic respiratory failure. Adequate protein intake is necessary to promote linear growth,
lung growth, and repair of damaged tissue. Protein needs for the preterm infant are high,
initially ranging from 3.5 to 4.2 g/kg/day. At present, there are no specific protein
recommendations for infants with sBPD. Providing adequate amounts of protein for
corrected gestational age and perhaps aiming toward the higher range may be beneficial to
compensate for periods of catabolic, hyper-metabolic states when protein turnover is high.
Medications, such as corticosteroids, also negatively impact protein accretion and body
composition; however, no studies are available for nutritional guidance in this population.
Individualized nutritional support with close monitoring and titration is important to avoid
over- or underfeeding in this population.
Although high fluid intake early in the NICU course of preterm infants is associated with
increased risk for BPD, there are no studies that directly address the role of fluid restriction
in established BPD. Fluid intake for subjects with sBPD is usually in the range of 130–150
mL/kg/day, and it should be kept in mind that fluid needs decrease over the first year of life.
It is reasonable to use conservative fluid intake in patients with sBPD, however, adequate
delivery of nutrients and water to meet both nutritional and physiological needs must be
assured. Adequate respiratory support is important from a nutritional standpoint in these
infants because cyanotic spells, increased work of breathing, and air hunger place these
infants at high risk for linear growth failure because of energy expenditure and stressinduced growth suppression.
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Metabolic bone disease (MBD), also called “osteopenia” or “rickets of prematurity,” is a
common finding in preterm infants, which is more common and severe in extremely preterm
infants.51–58 After preterm birth several postnatal factors contribute to the risk for MBD,
including parenteral and enteral supplements of calcium and phosphorus that cannot match
in utero sources,59 placement of preterm infants in the NICU in physical environments that
restrict movement,60 and exposure to multiple drug therapies that may affect overall bone
health.61–63 In addition, severe respiratory insufficiency may exacerbate feeding intolerance
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in infants with sBPD, who then may require prolonged parental nutrition, which provides
inadequate calcium and phosphorus and may also lead to aluminum accumulation that can
have a negative effect on bone formation.64 The typical biochemical picture of MBD
includes normal serum calcium, low serum phosphorus, and high serum alkaline
phosphatase concentrations.65–67 Radiographs are an inefficient diagnostic tool for MBD
and will not detect decreases of bone mineralization less than ~20%–30%.68 Bone density
scans more accurately reflect bone demineralization, but a bone density scan involves
radiation exposure, is not a portable device, and standards for preterm infants are
lacking.69,70 Although short-term effects of poor bone health seem to resolve with time,
long-term stunting effects have been documented in these infants into their teenage years.63
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Aspiration is a potential risk factor for persistent lung injury in the infant with sBPD.
Common sources of aspiration may include oral intake via dysfunctional swallowing,71
gastroesophageal reflux,72 a patient’s own oral secretions, and potentially increased upper
respiratory secretions during infections. Limited recurrent aspiration may result in chronic
respiratory symptoms, such as coughing, wheezing, or tachypnea (although aspiration in
preterm infants can frequently be “silent”);73 desaturations or hypercarbia;74 or poor weight
gain. More acute episodes of aspiration may result in pneumonia, tracheitis, or bronchitis,
often accompanied by an escalation of respiratory support. Although aspiration in the
preterm infant is often a function of delayed swallowing function maturation,71,75 other
factors to consider include neurologic insults or congenital or acquired airway anomalies,
such as vocal cord paresis or laryngeal clefts. Evaluation and ongoing assessments in the
NICU by an experienced occupational or speech therapist is strongly recommended for the
infant with sBPD. Diagnostic tests for dysphagia or reflux lack sensitivity and specificity for
aspiration risk in the infant with sBPD,71 thus, there remains controversy regarding surgical
treatment. However, in the appropriate clinical scenario, placement of gastrostomy tubes
with or without fundoplication may be warranted.76
Independently, feeding tubes may need to be considered in infants who orally feed safely,
but do not ingest enough calories for appropriate growth.
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Pulmonary exacerbations because of respiratory syncytial virus (RSV) infections, reactive
airways disease, and other problems may acutely alter swallowing function77 and baseline
gastrointestinal motility in the preterm infant with sBPD. Gastric distension may potentially
alter respiratory mechanics, thus, impairing ventilation. Impaired motility may increase
GERD, and hence, the risk for aspiration. In addition, increased tachypnea can preclude oral
intake in patients who orally feed. Strategies to consider during acute exacerbations include
the use of intravenous fluids or enteral rehydration solutions for gastrointestinal rest, timelimited placement of a nasogastric tube for patients who typically eat/drink orally, and/or the
use of continuous tube feeding.
Summary of Nutritional Management of sBPD
Nutritional success in patients with BPD is complicated by many factors including lack of
prospective data in this population, likely changing needs of the patient over time, growth
suppressive states of the patient, comorbidities, and high metabolic needs at times. However,
certain goals and concepts should be employed to strive for the best outcomes. Linear
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growth should be measured accurately and followed closely using appropriate standardized
growth curves. Weight for length should also be followed closely, seeking an ideal target
goal of ~50%. Titrations in nutrition should be considered at least weekly in concert with a
dietician familiar with this population. Strict attention should be given to the
nonpharmacologic support and comfort of the infant to minimize stress. Furthermore,
adequate respiratory support that allows for developmental activities and play must be
provided because this encourages a “progrowth” state.

Pharmacologic Therapy for sBPD
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Diverse respiratory system abnormalities contribute to altered lung function in different
compartments: central airways, bronchioles, and distal lung airspace or parenchyma. In
addition, respiratory system problems regarding central respiratory control, respiratory
muscle function, chest wall compliance, and others also contribute to BPD severity. Each
infant with sBPD may manifest a greater dysfunction in one part of the respiratory system
than others, and the role of any given drug therapy depends in part on the physiologic target
of that therapy.
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However, there is a paucity of data on the effectiveness of medications for treating infants
who have developed sBPD. The Cochrane Neonatal Systematic Reviews Library contains
over 300 reviews with BPD prevention or treatment as the focus of ~35 of those reviews, the
majority of which described studies with enrollment of infants early in the postnatal course
before the development of sBPD. Evidence supporting the use of pharmacologic agents is
limited and largely based on case reports, case series, and clinical experience, rather than
randomized controlled studies. All should be considered in the broader context of respiratory
support, including invasive and noninvasive ventilation, tracheostomy placement, and
nutritional management. However, these medications have been formally assessed for only
short-term surrogate outcomes, and marked center-to-center variability in drug use exists.9
This problem also leaves unanswered questions about the final risk-to-benefit ratio, which
remains largely unknown for many agents. In Table V, we have outlined the medications
used in sBPD with current dosing regiments described below, but these recommendations
are based on anecdotal usage as there is currently no evidence to guide their use in sBPD.
Large Airway Disease
Some infants with sBPD have dynamic airways obstruction because of tracheomalacia or
bronchomalacia, as well as possible fixed lesions, such as subglottic or tracheal stenosis,
granulomas, complete cartilage rings, and other central airway problems.
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Beyond manipulation of PEEP and surgical treatment of specific endobronchial lesions,
effective therapies are largely lacking for infants with many central airway problems.
Attempts to lower the work of breathing by using less dense gases such as helium-oxygen
mixtures (heliox) or treatment of severe tracheomalacia by aortopexy have produced mixed
results.
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The approach to reactive small airway disease is generally analogous to childhood asthma
and includes systemic or inhaled corticosteroids (fluticasone or budesonide), bronchodilators
(mainly albuterol, levalbuterol, or ipratropium), and mucolytic therapies. Bronchodilators
can lower airway resistance and improve respiratory compliance, however, whether these
effects provide sustained benefit in infants with sBPD is uncertain. The use of
bronchodilators in sBPD is widely variable between centers.33 Albuterol and levalbuterol are
adrenergic agonists that are used on various schedules to reduce bronchospasm. Clinically,
there can be variability in response to bronchodilators, which may be a result of genetic
variability in β2 adrenergic receptors as seen in children with asthma. However, this
variability in response has not been systematically assessed in patients with sBPD.
Ipratropium, an anticholinergic agent, is used by some practitioners for its putative effects in
reducing bronchoconstriction and excess secretions. Inhaled anticholinergic agents may
decrease gastrointestinal motility and result in dry/thickened secretions. Ipratropium is often
used in combination with albuterol for synergism. However, no trials have been conducted to
determine if combination therapy vs monotherapy is more efficacious. The use of inhaled
dornase has been suggested for patients with sBPD with thick secretions, although never
studied in randomized controlled trials. Acute exacerbation triggered by inflammation and
infection at the lower and medium airways has been treated with cyclic inhaled tobramycin,
but no definitive trials of its use in sBPD have been published. Other antibiotics, such as
azithromycin, may also have putative anti-inflammatory benefits.
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Systemic or inhaled steroid administration is commonly used for treating or preventing
pulmonary exacerbations in sBPD, sometimes on a daily or every other day dosing schedule.
Steroids may have a variety of beneficial effects as observed in other populations and
diseases including enhanced surfactant production, decreased inflammation, decreased
airway edema, decreased capillary leakage, and decreased lung fibrosis. Use of systemic
steroids is not benign as chronic use at doses typically used in the population with sBPD
may result in decreased growth, hypertension, bone demineralization, and developmental
delay. The appropriate dose, time, and type of steroid need to be evaluated to maximize
benefits and minimize risk. Individualizing steroid administration also will require better
ability to predict the clinical course of sBPD to determine when and how to administer
steroids in this population.
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Other anti-inflammatory medications, such as the leukotriene receptor antagonists
montelukast or zafirlukast, have been suggested as potentially beneficial in sBPD based on
their benefits in asthma and allergies. Montelukast may have benefit in its ability to provide
bronchodilation and to decrease inflammation, although data in sBPD are limited.78
Parenchymal or Distal Airspace Disease
Disease of the distal lung includes decreased alveolarization, dysmorphic vascular growth
with hypertensive remodeling, dilated lymphatics, prominent intrapulmonary shunt vessels,
and pulmonary edema. Diuretics (including furosemide, spironolactone, and chlorothiazide)
either alone or in combination, are commonly used on the theory that they are combating the
propensity of infants with BPD to develop pulmonary edema. Although short-term results of
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use of these medications have been favorable for improving lung compliance, no clinically
significant outcomes (such as changes in mortality, duration of mechanical ventilation,
oxygen dependence, length of hospital stay, etc) have been reported, and the use of diuretics
in sBPD is highly variable between centers.34 Diuretics can have adverse effects, including
hypercalciuria, nephrocalcinosis, metabolic alkalosis, and striking decreases in serum
potassium, phosphate, and other electrolytes. Nebulized furosemide has been shown to
provide short-term improvement in lung mechanics without systemic diuretic effects, but it
has never been studied as a long-term therapy.79
Systemic Hypertension
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Systemic hypertension can also occur in infants with sBPD, which may be related to
corticosteroid therapy, marked neurohormonal stimulation, renal disease, or other factors.80
Echocardiograms can reveal left ventricular hypertrophy or asymmetric septal hypertrophy.
Hypertension is treated empirically with antihypertensive medications and usually responds
to therapy over time.
Antireflux Medications
Gastric propulsive agents and gastric acid secreting blockers are often used to reduce the risk
of aspiration, but this use has not been confirmed in definitive trials. In fact, the routine use
of these agents has been described as unnecessary and potentially harmful in neonatology.81
Respiratory Muscle Stimulants
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The use of respiratory muscle stimulants, such as caffeine and doxapram, has been
suggested by a few clinicians based on theoretical improvements in lung function that could
potentially obviate the need for prolonged assisted ventilation or tracheostomy. However,
there is no empirical evidence available addressing this theoretical use of respiratory muscle
stimulants in established sBPD.
Summary of Pharmacology in sBPD
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There are few proven treatments for the management of sBPD. Given the number of these
infants and young children, the severity of their respiratory condition, and their guarded
long-term pulmonary function outlook, phase 2 and eventually phase 3 clinical trials are
warranted and desperately needed. Given the new combination therapies used for adults with
chronic obstructive pulmonary disease, we suggest that trials of the most promising of these
therapies be undertaken in combination with current therapies beginning at 36–40 weeks for
infants with sBPD. The clinically relevant primary outcomes for these investigations are to
reduce hospital days and reduce severity of pulmonary dysfunction, perhaps including
reduced need for tracheotomy.

Transitional and Postdischarge Care of Infants with sBPD
The primary criteria, steps, and goals for discharge should be met so that the infant/child
with sBPD can live and thrive at home in a safe environment while minimizing recurrent
hospitalizations. Improving the outcomes of infants with sBPD involves well-coordinated,
interdisciplinary teams that include links between inpatient and ambulatory care (Table VI).
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Infants with sBPD have longer lengths of initial hospitalizations and are at increased risk for
re hospitalizations because of respiratory illnesses after discharge.82 Furthermore, BPD is
associated with impaired postnatal lung growth,83 and in the absence of adequate recovery
particularly during the first 2 years of life, these children are at increased risk for chronic
obstructive pulmonary disease in later life. Comorbidities can further contribute to disease
severity,84–88 and failure to recognize or adequately treat comorbidities can contribute to
worse outcomes. Management of infants with sBPD in the home environment requires a
healthcare provider who is accessible to the family, can coordinate patient care among the
various subspecialists, and can recognize rapid changes in the health of the infant. Critical to
outpatient care is a subspecialist with respiratory expertise who may be either a
neonatologist or pulmonologist with expertise in the older child with BPD and comfortable
with respiratory medication management, and oxygen and ventilator weaning and titration.
This provider should be available for telephone consultation for families and other medical
professionals for questions regarding respiratory management at all times. Subspecialty
providers should be also comfortable counseling families on what to expect and how to
avoid exposures that may worsen outcomes such as daycare or secondhand smoke.89–92
Outpatient clinic capacity should be sufficient to handle regular clinic visits with visit
frequency dependent on the child’s needs, which could range from weekly to every 3 months
especially during the first 2 years of life, a period of rapid postnatal lung growth and during
which children with BPD are more likely to be hospitalized for respiratory illnesses.
Discharge Preparation
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The risk of death after discharge from the NICU is likely highest in patients with more
severe respiratory disease, patients with tracheostomies, and patients with a history of
pulmonary hypertension. Preterm infants are at higher risk for death at home compared with
full term infants, and infants with BPD may have abnormal responses to hypoxia, placing
them at higher risk for adverse events at home.93 For preterm infants with PH, mortality has
been reported to be as high as 12%–38%.24 In infants and children with sBPD, the risk of
death in association with home mechanical ventilation has reported to be as high as 19%.94
In addition to mortality, infants with BPD are subject to significant morbidities. Various
studies have reported that between 49% and 58% of infants required readmission within the
first two years of life.95–97
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Adequate caregiver training is essential to address outpatient needs of a child with sBPD and
is perhaps the most important part of a safe discharge to home, as some of the morbidity and
mortality following discharge may be preventable. Before discharge, the team should
establish a BPD action plan (Table VII). Caregivers need to demonstrate proficiency in all
aspects of care. The home caregiver must be able to recognize signs of respiratory distress
and illness in their child and to address emergency health issues in the home environment,
such as emergency tracheostomy changes, need for inhalational medications, and/or
equipment failure.98 Poor adherence to respiratory medications was associated with an
increased risk of emergency department visits and rescue inhaled beta-agonist use and
increased activity limitations in infants with sBPD.99 The same study reported that
medication non-adherence was associated with caregiver concerns regarding medication
efficacy and side effects rather than sociodemographic or clinical factors, therefore, the risks
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and benefits of each therapy should be explained to the caregiver. Overall, it is highly
advisable to have at least 2 caregivers trained for the appropriate cares, especially for an
infant or child with a tracheostomy.98
In addition to family caregivers, some infants may require home nursing care as well.
Determination of home nursing hours or visits should be finalized and discussed with the
caregiver and payers prior to discharge. Continuous monitoring by trained caregivers 24
hours per day, 7 days per week is required, including substantial home nursing presence.98
Lastly, anticipatory support from social work should also address potential insurance
concerns that may arise from medical costs in the outpatient setting, travel, and time
commitments required to attend outpatient visits, as well as discussions of the adjustment
process for caring for a chronically ill child at home, including issues of social isolation and
management of communication issues with multiple health care professionals.100
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Discharge of the Tracheostomy/Ventilator-Dependent Infant with sBPD

Author Manuscript

The child with chronic respiratory failure who is dependent on a tracheostomy and ventilator
can create specific challenges for a successful transition to home. Infants and young children
with tracheostomies with or without home ventilation are at increased risk for mortality
because of their underlying lung disease and the potential for unobserved plugging of their
tracheostomy tube or disconnection from the ventilator leading to cardiopulmonary arrest. In
a retrospective study, Edwards et al101 reported 47 deaths (21% mortality rate) among 228
children on home ventilation with 49% of deaths being unexpected, including 19% of deaths
being related to tracheostomy complications. Although there are no guidelines or consensus
statements regarding the outpatient management of sBPD at the current time, the 2008 the
American Academy of Pediatrics Committee on Fetus and Newborn updated a 1998 policy
statement discussing the hospital discharge of the high-risk neonate, much of which is
applicable to infants with sBPD.102 Approaches to the home care of ventilated infants was
recently addressed by a consensus group of the American Thoracic Society.98
In keeping with the imperative to train family members as caregivers, a comprehensive
checklist that addresses specific issues that may arise with tracheostomy and continue after
discharge should be created and completed to address the personal needs of each child and
caregiver prior to discharge. Lastly, a recent study has shown that a well-organized
interdisciplinary team that includes inpatient and outpatient components can reduce duration
of hospitalization and enhance long-term survival.103
Strategies for Home Ventilation
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For infants who are ventilator dependent with type 2 sBPD, home monitoring with both a
pulse oximeter and a cardiorespiratory monitor should be considered.98 The ability to
monitor saturations is essential for adjusting ventilator and oxygen support in the outpatient
setting, but continuous oxygen saturation monitoring is often not able to be maintained
secondary to limitations on provision of pulse oximeter probes and by skin breakdown or
burns when using nondisposable probes. However, use of a pulse oximeter is indicated when
infants are not directly observed. Subspecialty providers should be comfortable with
weaning children from chronic ventilation. Guidelines for weaning from chronic ventilation
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are uncertain, but recent recommendations from the American Thoracic Society suggest that
children requiring chronic ventilation should have a comprehensive medical home
comanaged by a generalist and a respiratory subspecialist.98 Polysomnography is more
sensitive than clinic-based assessments for weaning support and may be useful in
determining levels or types of respiratory support and determining optimal timing for
weaning off of home ventilation.104 When polysomnography is not available, alternative
approaches, such as pulse oximetry and end tidal CO2 monitoring, should be considered. In
some cases, inpatient observation may be required for ventilator weaning, escalation of
support, or capping of tracheostomies for safety purposes.
Strategies for Home Oxygen Therapy
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Children with sBPD on oxygen should be monitored closely in the outpatient setting, and
although the use of home pulse oximeters for children on oxygen is often necessary, it can
cause many false alarms and stress caregivers. When weaning off supplemental oxygen, the
basic tenet is that pulse oximetry should be used and oxygen saturations should be
maintained at or above 92%, particularly if pulmonary hypertension is present.37 In the
home setting, only 100% oxygen can be delivered via nasal cannula, and, therefore, flow
rate is titrated during weaning in the outpatient setting. Few studies have been performed to
determine the appropriate flow rate from which oxygen can be safely discontinued. In a
small prospective study, Simoes et al105 demonstrated that infants on 20 mL/kg or less of
oxygen were more successful at weaning to room air. A recent study of 20 pediatric
pulmonary programs in the US found little consensus regarding weaning strategies from
supplemental oxygen, but most used prolonged home assessments of oxygenation by
nocturnal pulse oximetry.106 It is important to note that in addition to oxygen saturation,
achieving adequate somatic growth and prevention or resolution of the signs of PH are
important outcomes to consider prior to discontinuing supplemental oxygen therapy. When
growth is poor, the use of nocturnal oxygenmay need to be extended. In summary, for many
infants with sBPD, safe outpatient use of supplemental oxygen can allow infants to continue
to progress in the home environment rather than in the NICU. Further research is needed to
determine optimal weaning strategies.
Monitoring Lung Function
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Infant pulmonary function testing (PFTs) can be useful in assessing severity of lung
dysfunction and response to treatment. Limitations to infant PFTs include use of sedation
and lack of availability at many tertiary care centers. All children with sBPD should undergo
regular PFTs when they are able to follow directions because abnormalities in pulmonary
function are often missed or underestimated in children with BPD. Small airway dysfunction
manifested by hyperinflation and reactive and fixed small airway obstruction has been
reported in school age children with a history of BPD.107 Oxygen desaturation with exercise
or with lower respiratory tract illnesses can frequently occur in children with sBPD.108
Management of Respiratory Viruses and Lower Respiratory Illnesses
Respiratory infections can be life-threatening in children with sBPD and are more likely to
result in hospitalization, including a high rate of pediatric intensive care unit admissions. In
a cohort from the United Kingdom, 73% of infants with BPD required at least 1 readmission
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in the first 2 years of life and 27% had 3 or more hospitalizations.109 Historically, most
admissions in children with BPD have been due to lower respiratory tract infections (LRTIs)
secondary to RSV, but human metapneumovirus and rhinovirus LRTIs are common.110–112
The use of palivizumab, a monoclonal antibody against the F glycoprotein in RSV, has
reduced the morbidity and mortality associated with RSV infection.111,112 Because
respiratory infections can be more severe in children with BPD, these children require closer
monitoring with the onset of viral symptoms. Infants who have recently weaned off
supplemental oxygen are more likely to become hypoxic with viral exposures.113 Although
management is focused on supportive care and monitoring to ensure that the child remains
well saturated and well hydrated, a trial of inhaled bronchodilators or inhaled steroids may
be helpful.
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Although bronchiolitis usually is a self-limited illness, infants with BPD who require
hospitalization for bronchiolitis are at increased risk for wheezing with subsequent viral
exposures. Thus, the use of preventative measures is critical in this high-risk population.
Vigilance in receiving all doses of palivizumab during the typical 6-month window of RSV
infection reduces the risk of severe RSV disease, but efforts should be made to limit the
impact of other viral pathogens. The use of hand hygiene is important, especially with
siblings who enter the home from school or preschool exposures. The increased severity of
LRTIs in infants with sBPD may also contribute to the increased prevalence of cough and
wheezing that persists beyond the acute infection.
Neurodevelopmental Outcomes
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Children with sBPD should be evaluated by experts in child development and be enrolled in
an early infant intervention program that can provide home therapy visits (when possible) to
address developmental issues common in pretermchildren. Nonoxygen-dependent children
with BPD have been reported to catch up developmentally at 2 years of age, whereas those
initially discharged home on oxygen have been reported to catch up by 4 years of age,114 but
infants who required mechanical ventilation at 36 weeks PMA were 6 times more likely to
have quadriparesis compared with infants who required only supplemental oxygen at 36
weeks PMA.115 Close neurodevelopmental follow-up can provide parents with reassurance
and education on appropriate developmental milestone attainment, specific to the child’s
chronologic age and degree of prematurity.

Conclusions
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Despite major improvement in the care and outcomes of extremely preterminfants over the
past few decades, some infants develop especially severe chronic lung disease that includes
those who require prolonged ventilator support (or type 2 sBPD). More basic and
translational research is needed to better understand the pathobiology of sBPD, including
mechanisms that cause more severe disease than in other preterm infants, as well as
epidemiologic and outcomes research to elucidate risk factors and patterns that may lead to
earlier identification of at risk infants (Table II). Finally, organized approaches for clinical
interventions and trials that involve multiple centers are necessary due to the relatively small
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numbers of sBPD at each site. Such approaches may help provide better information to
develop new care guidelines to enhance the long-term outcomes of infants with sBPD.

Glossary
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BPD

Bronchopulmonary dysplasia

CCBs

Calcium channel blockers

CPAP

Continuous positive airway pressure

FiO2

Fraction of inspired oxygen

GERD

Gastroesophageal reflux disease

iNO

Inhaled nitric oxide

LRTIs

Lower respiratory tract infections

MBD

Metabolic bone disease

NICU

Neonatal intensive care unit

NIH

National Institutes of Health

PEEP

Positive end expiratory pressure

PFTs

Pulmonary function testing

PH

Pulmonary hypertension

PMA

Postmenstrual age

RSV

Respiratory syncytial virus

sBPD

Severe BPD

Ti

Inspiratory time

Vt

Tidal volume
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Charisse Lachica, MD, Winston Manimtim, MD, Michael F. Nyp DO MBA, Tamorah
Lewis, MD, PhD; Children’s Hospital Colorado, Aurora, CO: Jody Thrasher, RN, Alicia
Grenolds, PNP; Childrens Hospital of Philadelphia, Philadelphia, PA: Howard Panitch, MD;
Erik A. Jensen, MD; David A. Munson, MD; William W. Fox, MD; Jason Z. Stoller, MD,
Kathryn Maschhoff, MD; Kristen J. McKenna, MD; Nicolas Bamat, MD; Vanderbilt
University, Nashville, TN: Steven Steele, BA; Brown University, Providence, RI: Shukla
Khushbu, MD; Baylor University, Houston, TX: Sushma Nuthakki, MD; Nationwide
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Imaging of sBPD: Chest radiograph (left) and image from computed tomography (CT) scan
illustrate radiographic abnormalities of type 2 sBPD. Note the severe cystic disease present
on the CT scan.
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Illustration of A, 2-zone disease vs B, multizone (heterogeneous) disease. A, Chest CT with
2 zones in a patient with acute respiratory distress syndrome. B, Chest CT in a patient with
type 2 sBPD and diffuse, heterogeneous disease. C, Schematic illustrating concept of
multizone disease. Time constant, T = resistance x compliance. Reprinted with permission
from Abman et al.29
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Author Manuscript

BPD definition with severity
Relative incidence
(Data from
Ehrenkranz et al5)

Postdischarge
mortality (Data
from Ehrenkranzet
al5)

BPD severity

Definition (Modified from Jobe and Bancalari4)

None

O2 treatment <28 d and breathing room air at 36 wk PMA or discharge
home, whichever comes first

23.1%

1.8%

Mild

O2 treatment at least 28 d and breathing room air at 36 wk PMA or discharge
home, whichever comes first

30.3%

1.5%

Moderate

O2 treatment at least 28 d and receiving <30% O2 at 36 wk PMA or
discharge home, whichever comes first

30.2%

2.0%

Severe (type 1)

O2 treatment at least 28 d and receiving ≥30% O2 or nasal CPAP/HFNC at
≥36 wk PMA

16.4%

4.8%

Severe (type 2)

O2 treatment at least 28 d and receiving mechanical ventilation at ≥36 wk
PMA.

Author Manuscript

HFNC, high flow nasal cannula; O2, oxygen.
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Table II

Author Manuscript

Identification of unique research needs to enhance our understanding of sBPD (Modified from Collaco et al24)
Epidemiology
1

To quantify the current incidence of sBPD among preterm infants

2

To understand the natural history and outcomes of sBPD by large prospective studies in different areas of the world

3

To understand the economic impact of sBPD on families and society

4

To understand the impact of sBPD on quality of life in infants and their families

Risk factors
1

To identify prenatal and postnatal factors that increase risk of developing sBPD in preterm infants

2

To identify risk factors that may exacerbate sBPD in preterm infants, including viral infections, lower respiratory tract disease,
upper airway obstruction, intermittent hypoxia and hypercarbia, feeding problems with aspiration, and gastroesophageal reflux

3

To understand the role of pulmonary vascular disease in determining the severity of BPD

Author Manuscript

Pathophysiology
1

To further identify clinical, epidemiologic and biomarker features to better phenotype subtypes of sBPD

2

To identify genetic and epigenetic factors that influence the development and severity of sBPD

Diagnosis
1

To determine the best non-invasive studies for diagnosis and following infants with sBPD

Management
1

To develop guidelines for treatment and preventative strategies for preterm infants at risk for the development of sBPD

2

To determine the optimal prescription of existing medications in preterm infants with sBPD

3

To determine optimal ventilatory strategies in the neonatal intensive care unit and home settings

4

To identify newer therapeutic agents for the treatment of sBPD
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Table III

Author Manuscript

Comparison of ventilator strategies and goals during progression of early disease to established sBPD
(modified from Abman and Nelin29)
Early (prevention)

Strategies to prevent acute lung injury

Low tidal volumes (3–5 mL/kg)
Short inspiratory times (0.2–0.3 seconds)
Increased PEEP for lung recruitment without overdistension

Strategies for gas exchange

Adjust FiO2 to target SpO2 (range: 91%–95%)
Permissive hypercapnia

Late (established BPD)

Strategies for gas exchange

Marked regional heterogeneity
Larger tidal volumes (10–12 mL/kg)
Longer inspiratory times (≥0.6 s)
Airways obstruction

Author Manuscript

Slower rates allow for better emptying, especially with larger tidal volumes
(10–20 bpm)
Complex roles for PEEP with dynamic airway collapse
Interactive effects of ventilator strategies
Changes in rate, tidal volume, inspiratory and expiratory times, and
pressure support are highly interdependent
Overdistension can increase agitation and paradoxically worsen ventilation
Strategies for gas exchange

Adjust FiO2 to target higher SpO2 (92%–95%)
Permissive hypercapnia to facilitate weaning

Author Manuscript
Author Manuscript
J Pediatr. Author manuscript; available in PMC 2017 August 18.

Abman et al.

Page 33

Table IV

Author Manuscript

Considerations for pulmonary hypertension in sBPD (modified from Abman and Nelin;29 Abman et al37)
Diagnoses
1

Screening via echocardiography (assess for tricuspid regurgitant jet velocity, septal flattening, RV dilation, and other parameters
of RV function)
a.

If no pulmonary hypertension present:

b.

If pulmonary hypertension present:

Rescreen every 1–2 mo until significant improvement in respiratory status

i.

i.

Evaluate and treat respiratory disease, including assessing for hypoxemia, aspiration, and structural
disease

ii.

Avoid hypoxemia (maintain oxygen saturations between 92% and 95%)

iii.

Consider therapeutic agents as below

Pharmacologic treatments

Author Manuscript

1

Pretreatment: Cardiac catheterization should be considered prior to initiating long-term therapy to assess severity of disease and
potential contributing factors, such as left ventricular diastolic dysfunction, anatomic shunts, pulmonary vein stenosis, and
systemic collaterals

2

Therapies

3

a.

iNO can be started at 20 ppm for symptomatic or severe pulmonary hypertension

b.

Transition from iNO to sildenafil as feasible starting at 0.5 mg/kg q8h and advancing to 2 mg/kg q6h. Monitor for
desaturations secondary to V/Q mismatch and systemic hypotension.

c.

If unable to wean from iNO, consider the addition of an ETRA or a prostacyclin analog. Liver function should be
monitored if on an ETRA.

Monitoring: Cardiac catheterization or serial echocardiography is recommended to monitor response to therapy

ETRA, endothelin receptor antagonist; RV, right ventricular; V/Q, ventilation-perfusion.
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Table V

Author Manuscript

Pharmacology of sBPD
Categories

Medications

Dosing

Comments

Diuretics (Enteral dosing)

Furosemide

1–2 mg/kg/dose q12–24h

Often PRN

Chlorothiazide

20–40 mg/kg/d divided q12h

Spironolactone

2–4 mg/kg/d divided q12–24h

Albuterol

2.5 mg nebulized or 2 puffs q4–12h

Often PRN

Ipratropium

0.5 mg q6–12h

Often PRN

Levalbuterol

0.31–1.25 mg or 2 puffs q4–12h

Often PRN

Beclomethasone

2 puffs q12h

40 or 80 mcg MDIs

Budesonide

1 neb q12–24h

0.25 or 0.5 mg nebs

Fluticasone

2 puffs q12h

44, 110, 220 mcg MDIs

Bosentan

½ tab BID PO

Sildenafil

0.25–0.5 mg/kg/dose q 6–8 h

Treprostinil

Starting dose: 2 ng/kg/min iv or SQ

Erythromycin

2–4 mg/kg/dose q6–8h

Lansoprazole

0.5–1.0 mg/kg/dose BID

Metoclopramide

0.1–0.2 mg/kg/dose q6–8 h

Omeprazole

0.5–1.5 mg/kg/d

Ranitidine

2–4 mg/kg/d divided q8–12 h

Bronchodilators

Inhaled corticosteroids

Pulmonary hypertensive agents
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Antireflux agents (enteral dosing)

MDI, metered dose inhaler; PRN, as needed.
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Table VI

Author Manuscript

Composition of interdisciplinary teams for the management of sBPD
Disciplines

Inpatient (NICU/PICU)

Outpatient

Team leader/coordinator

Neonatologist, pulmonologist, critical care physician,
hospitalist, or nurse practitioner

Primary care physician

Respiratory

Neonatologist or pulmonologist, and respiratory therapists

Neonatologist or pulmonologist

Cardiac

Cardiologist

Cardiologist

Airway

Otolaryngologist

Otolaryngologist

Gastrointestinal

Gastroenterologist and/or nutritionist

Gastroenterologist and/or nutritionist

Development

Neonatologist and therapists (also child life)

Neonatologist or developmental pediatrician, and
therapists

Nursing

Nurses

Home nurses

Social

Social worker/and/or chaplain

Social worker
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PICU, pediatric intensive care unit.
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Table VII

Author Manuscript

sBPD action plan
When to give PRN meds
When to suction or change the tracheostomy tube
When to seek telephone consultation
When to go to the emergency department
When to call 911
Summary of previous and active medical issues
List of healthcare providers
List of medications including dosing and frequency
Current oxygen/ventilator settings
Summary of helpful information for caregivers and healthcare providers not familiar with the child
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